Cargando…
Cancer treatment in the last 6 months of life: when inaction can outperform action
When an investigational anticancer drug is being tested, demonstration of improvement in overall survival (OS) will generally lead to regulatory approval. However, the value that improvement in OS adds to patients’ lives is guided largely by the context of the improvement and accompanying trade-offs...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cancer Intelligence
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931812/ https://www.ncbi.nlm.nih.gov/pubmed/29743946 http://dx.doi.org/10.3332/ecancer.2018.826 |